Nonanoic Acid Benzylamide

Nonanoic Acid Benzylamide

SCHEMBL3280214

CCCCCCCCC(=O)NCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 7/20 1.00
FAAH O00519 3/20 0.83
MEN1 O00255 2/20 0.83
KMT2A Q03164 2/20 0.83
CNR2 P34972 3/20 0.79
CNR1 P21554 2/20 0.79
GAA P10253 1/20 0.74
CYP3A4 P08684 1/20 0.67
CYP2C19 P33261 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
POLB P06746 1/20 0.64
TRPV1 Q8NER1 1/20 0.64
ALDH1A1 P00352 1/20 0.62
HPGD P15428 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28136678 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL2088173 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL16714726 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL2166861 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL29052372 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL5696750 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL2524088 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
N-Benzyldodecanamide SCHEMBL3977374 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL5471650 1.00 EPHX2 (1.00) EPHX2FAAHMEN1KMT2ACNR2
SCHEMBL1516109 0.98 EPHX2 (0.97) EPHX2FAAHMEN1KMT2ACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510359-A Synthesis method of N-benzyl-N-nonanamide compound 中国人民解放军61699部队 2024-02-06 CN claimed
CN-1658866-A Tri-substituted heteroaryls and methods of making and using the same BIOGEN INC (US) 2005-08-24 CN claimed
US-12351819-B2 Method for removing undifferentiated pluripotent stem cells ACADEMIA SINICA (TW) 2025-07-08 US disclosed
CN-117510359-A Synthesis method of N-benzyl-N-nonanamide compound 中国人民解放军61699部队 2024-02-06 CN disclosed
CN-117510359-A Synthesis method of N-benzyl-N-nonanamide compound 中国人民解放军61699部队 2024-02-06 CN disclosed
CN-117510359-A Synthesis method of N-benzyl-N-nonanamide compound 中国人民解放军61699部队 2024-02-06 CN disclosed
CN-116041196-A Novel method for catalytic synthesis of amide bond 烟台南山学院 2023-05-02 CN disclosed
EP-2488032-B1 PROSTAGLANDIN TRANSPORTER INHIBITORS AND USES THEREOF EINSTEIN COLL MED (US) 2016-11-02 EP disclosed
US-8309538-B2 Capsaicinoid decontamination compositions and methods of use KAPSO, LLC (US) 2012-11-13 US disclosed
WO-2010144055-A1 NOVEL COMPOUNDS AND USES THEREOF NANYANG POLYTECHNIC (SG) 2010-12-16 WO disclosed
US-20100086626-A1 CAPSAICINOID DECONTAMINATION COMPOSITIONS AND METHODS OF USE KAPSO, LLC 2010-04-08 US disclosed
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof L'OREAL (FR) 2008-07-10 US disclosed
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof L'OREAL (FR) 2008-07-10 US disclosed
US-20060198806-A1 Capsaicinoid decontamination compositions and methods of use KAPSO, LLC 2006-09-07 US disclosed
CN-1658866-A Tri-substituted heteroaryls and methods of making and using the same BIOGEN INC (US) 2005-08-24 CN disclosed
US-20010051184-A1 METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES NEUVOLA II, LLC 2001-12-13 US disclosed
WO-2000070949-A1 METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES HENG MADALENE C Y (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051184-A1 METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES CAMK1, PNCK, CAMK1D EPHX2 2490/4885FAAH 701/4885MEN1 3911/4885
US-12351819-B2 Method for removing undifferentiated pluripotent stem cells ALPG, UGGT1, GYPA EPHX2 237/4885FAAH 4572/4885MEN1 3780/4885
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof KRT18, TYR, CRYAA EPHX2 1447/4885FAAH 859/4885MEN1 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.